Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director · CEO, President, Chairman · 10% owner | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,164,600 |
Reported balance
After 2026-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 400 · Balance 2,164,600 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,825 |
Reported balance
After 2026-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-01 · Sale · Disposed 775 · Balance 2,163,825 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,424 |
Reported balance
After 2026-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-06-01 · Sale · Disposed 401 · Balance 2,163,424 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,162,500 |
Reported balance
After 2026-06-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-06-01 · Sale · Disposed 924 · Balance 2,162,500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Roger E. Susi Revocable Trust | 162,950 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 162,950 |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew Susi 2008 Dynasty Trust | 2,062,500 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,062,500 F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2016 Filed Dec 1, 2016 12:24 UTC | IRADIMED CORP IRMD · Entity 4896 | PurchaseCommon Stock | 5,000 | $11.24 | $56,190.00 |
DisclosureSEC source: 0001140361-16-088306 · doc1.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, President, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.15 to $11.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 21:46 UTC | IRADIMED CORP IRMD · Entity 4896 | PurchaseCommon Stock | 5,000 | $10.46 | $52,280.00 |
DisclosureSEC source: 0001140361-16-086963 · doc1.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, President, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.20 to $10.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.